SBILIFE - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.8
| Stock Code | SBILIFE | Market Cap | 1,88,030 Cr. | Current Price | 1,875 ₹ | High / Low | 2,133 ₹ |
| Stock P/E | 76.1 | Book Value | 190 ₹ | Dividend Yield | 0.14 % | ROCE | 15.0 % |
| ROE | 13.7 % | Face Value | 10.0 ₹ | DMA 50 | 1,887 ₹ | DMA 200 | 1,892 ₹ |
| Chg in FII Hold | -0.37 % | Chg in DII Hold | 0.41 % | PAT Qtr | 805 Cr. | PAT Prev Qtr | 577 Cr. |
| RSI | 50.9 | MACD | -3.80 | Volume | 9,70,874 | Avg Vol 1Wk | 8,32,173 |
| Low price | 1,720 ₹ | High price | 2,133 ₹ | PEG Ratio | 5.94 | Debt to equity | 0.00 |
| 52w Index | 37.5 % | Qtr Profit Var | -1.09 % | EPS | 24.6 ₹ | Industry PE | 72.8 |
📊 Financials: SBILIFE has demonstrated strong scale with a market cap of ₹1,88,030 Cr. Quarterly PAT rose to ₹805 Cr. from ₹577 Cr., though profit variation shows -1.09% decline sequentially. ROE at 13.7% and ROCE at 15.0% indicate healthy returns. Debt-to-equity is 0.00, reflecting a debt-free balance sheet. Cash flows remain stable, supported by insurance premium inflows.
💹 Valuation: Current P/E of 76.1 is higher than the industry average of 72.8, suggesting premium valuation. P/B ratio (~9.8) is significantly above book value ₹190. PEG ratio at 5.94 indicates expensive growth relative to earnings. Intrinsic value appears lower than CMP ₹1,875, limiting near-term upside.
🏦 Business Model: SBILIFE operates as a leading life insurance provider in India, leveraging SBI’s distribution strength and brand trust. Its competitive advantage lies in bancassurance, diversified product portfolio, and strong persistency ratios. However, growth is sensitive to regulatory changes and competition from private insurers.
📉 Entry Zone: RSI at 50.9 suggests neutral momentum, while MACD at -3.80 indicates mild bearishness. A good entry zone could be around ₹1,750–₹1,800 for accumulation. Long-term investors may hold, given the company’s strong fundamentals and debt-free status.
Positive
- 📈 Strong brand and distribution via SBI.
- 💰 Debt-free balance sheet (0.00 debt-to-equity).
- 📊 Healthy ROCE (15.0%) and ROE (13.7%).
Limitation
- ⚠️ High valuation with P/E at 76.1 vs industry 72.8.
- 📉 Sequential profit variation (-1.09%).
- 🔄 Sensitive to regulatory and market cycles.
Company Negative News
- 📉 Decline in FII holding (-0.37%).
- ⚠️ Stock trading slightly below DMA 200 (1,892).
Company Positive News
- 📊 Quarterly PAT growth YoY from ₹577 Cr. to ₹805 Cr.
- 📈 Increase in DII holding (+0.41%).
Industry
- 💹 Industry PE at 72.8, slightly lower than SBILIFE’s 76.1.
- 📊 Life insurance penetration in India is rising steadily.
- 🏦 Competition from private insurers and fintech-driven insurance platforms.
Conclusion
⚖️ SBILIFE is a fundamentally strong, debt-free insurer with consistent returns and strong brand advantage. However, valuations are stretched, limiting short-term upside. Long-term investors may accumulate near ₹1,750–₹1,800, with confidence in the company’s growth trajectory and industry expansion.
For a broader perspective, you could explore SBILIFE peer comparison or a technical chart analysis to complement this fundamental view.